5
Participants
Start Date
October 31, 2012
Primary Completion Date
January 31, 2015
Study Completion Date
January 31, 2015
GD2 CAR modified Tri-virus specific cytotoxic t-cells
This is a feasibility study to assess safety of an infusion of chimeric-antigen receptor gene modified allogeneic virus specific T lymphocytes after reduced intensity allogeneic stem cell transplant. Three patients were treated and safety was evaluated. Patients received a single infusion of 2x10e6/m2 donor derived, GD2 CAR modified, tri-virus specific CTL performed 30-120 days after allogeneic stem cell transplantation
Children's Mercy Hospital, Kansas City
Center for Cell and Gene Therapy, Baylor College of Medicine
OTHER
Children's Mercy Hospital Kansas City
OTHER